US2003228666A1PendingUtilityA1

Novel human thrombopoietin mutein

51
Assignee: DAE WOONG PHARMAPriority: Jun 30, 1998Filed: May 20, 2003Published: Dec 11, 2003
Est. expiryJun 30, 2018(expired)· nominal 20-yr term from priority
Inventors:Joo ChungSang Kyu ParkSang Myoung JuHyea Kyung AhnSeung-Wook LimWoo Ik ChangSeung Kook ParkYeo-Wook KohJi-Soo Park
C07K 14/524
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to novel human thrombopoietin (; hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.

Claims

exact text as granted — not AI-modified
What is claimed is  
     
         1 . Human thrombopoietin derivative which derived from human thrombopoietin (hTPO) described by SEQ ID NO: 30; which has at least one additional N-linked glycosylation site; and which is selected from the group comprising: 
 [Asn 108 ] hTPO;    [Asn 117 ] hTPO;    [Asn 147 ] hTPO;    [Asn 153 ] hTPO;    [Asn 164 ] hTPO;    [Asn 193 ] hTPO;    [Asn 117 , Asn 147 ] hTPO;    [Asn 117 , Asn 164 ] hTPO;    [Asn 108 , Asn 147 ] hTPO;    [Asn 108 , Asn 164 ] hTPO;    [Asn 147 , Asn 164 ] hTPO;    [Asn 117 , Asn 147 , Asn 164 ] hTPO;    [Asn 108 , Asn 147 , Asn 164 ] hTPO;    [Asn 108 , Asn 117 , Asn 164 ] hTPO;    [Asn 157 , Asn 164 ] hTPO;    [Asn 162 , Ser 164 ] hTPO;    [Asn 162 , Thr 164 ] hTPO;    [Asn 153 , Ser 155 , Asn 164 ] hTPO;    [Asn 153 , Thr 155 , Asn 164 ] hTPO;    [Asn 159 , Ser 161 , Asn 164 ] hTPO;    [Asn 159  , Thr 161 Asn 164 ] hTPO;    [Asn 166 , Ser 168 ] hTPO;    [Asn 166  , Thr 168 ] hTPO; and    [Asn 164 , Asn 168 ] hTPO.    
     
     
         2 . The human thrombopoietin derivative of  claim 1  which is [Asn 164 ] hTPO, [Asn 193 ] hTPO, [Asn 108 , Asn 117 , Asn 164 ] hTPO, or [Asn 157 , Asn 164 ] hTPO.  
     
     
         3 . Recombinant gene encoding human thrombopoietin derivative of  claim 1 .  
     
     
         4 . Recombinant gene encoding human thrombopoietin derivative of  claim 2 .  
     
     
         5 . Eukaryotic expression vector containing the recombinant gene of  claim 3 .  
     
     
         6 . The eukaryotic expression vector of  claim 5  which is p40433, p40434, p40449, p40458, pD40433, pD40434, pD40449, or pD40458.  
     
     
         7 . Mammalian cell line CHO K-1/p40433 (Accession NO: KCTC 0495BP) transfected with the expression vector p40433 of  claim 6 .  
     
     
         8 . Mammalian cell line CHO dhfr-/pD40434 (Accession NO: KCTC 0630BP) transfected with the expression vector pD40434 of  claim 6 .  
     
     
         9 . Mammalian cell line CHO dhfr-/pD40449 (Accession NO: KCTC 0631BP) transfected with the expression vector pD40449 of  claim 6 .  
     
     
         10 . Mammalian cell line CHO dhfr-/pD40458 (Accession NO: KCTC 0632BP) transfected with the expression vector pD40458 of  claim 6 .  
     
     
         11 . Process of preparing the human thrombopoietin derivative of  claim 1  wherein a mammalian cell line containing the recombinant gene of  claim 3  is used to obtain the human thrombopoietin derivative of  claim 1 .  
     
     
         12 . Pharmaceutical composition containing the human thrombopoietin derivative of  claim 1  which is used for the treatment of thrombocytopenia.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.